The primary composite endpoint (cardiovascular death or worsening heart failure) was reached in 9,9% of the tirzepatide arm versus 15,3% of the placebo arm (HR 0,62, p=0,026)
Some anti-diabetic medications are linked with an increased risk of weight gain or hypoglycemia which may reduce the efficacy of the intended anti-hyperglycemic effects of these therapies
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not
These results are from real GoalBMI Wellness patients across both insurance-covered and self-pay programs all under the same physician supervision and monitoring protocols
If you're currently on a prescription GLP-1 injection and you're thinking about switching, please speak to your healthcare provider first
Now the trend is catching on in the UK